IKK-16 is a selective inhibitor of IκB kinase (IKK), particularly targeting the IKKβ subunit. It is widely used in research to suppress NF-κB signaling, a key pathway involved in inflammation, immune response, and cell survival. Due to its ability to block NF-κB activation, IKK-16 has been studied in models of inflammatory diseases such as arthritis, sepsis, and inflammatory bowel disease. It also shows potential in cancer research, where constitutive NF-κB activity supports tumor growth and resistance to therapy. By inhibiting this pathway, IKK-16 can enhance the effectiveness of chemotherapeutic agents and promote apoptosis in certain cancer cell types. Its use is primarily limited to preclinical studies, serving as a tool compound to explore the therapeutic benefits of IKK and NF-κB inhibition.